conjugated PEI/anti-CD133 mAb plasmid-based gene therapy (Discovery genomics)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameconjugated PEI/anti-CD133 mAb plasmid-based gene therapy (Discovery genomics)

Drug Alias NameBTSC-targeted suicide gene therapy (Discovery genomics)

ClassificationCell and gene therapy > Gene therapy > PlasmidBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionCD133 inhibitors

TargetsCD133

Therapy Area/IndicationsBrain Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesDiscovery Genomics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDiscovery Genomics Inc

Active IndicationsN/A

Inactive IndicationsBrain Neoplasms

Other Information

ATC CodeN/A